Modern Approaches To The Diagnosis And Comprehensive Treatment Of Multiple Sclerosis: Clinical And Neuroimmunological Aspects

Yakubova Marhamat Mirakramovna; Rizakulov Valijon Alisher ugli

Authors

Yakubova Marhamat Mirakramovna Tashkent State Medical University
Rizakulov Valijon Alisher ugli Tashkent State Medical University

Keywords:

multiple sclerosis, demyelinating disease, neuroimmunology, disease-modifying therapy, neurological rehabilitation

Abstract

Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease of the central nervous system characterized by inflammatory lesions, neuroaxonal damage, and progressive neurological dysfunction. Early diagnosis and appropriate treatment are essential for preventing relapses and reducing long-term disability. This article examines modern approaches to the diagnosis and comprehensive management of multiple sclerosis, focusing on clinical manifestations, magnetic resonance imaging, cerebrospinal fluid biomarkers, and disease-modifying therapies. A narrative analysis of published clinical studies and international recommendations was conducted. The findings demonstrate that the integration of neurological examination, advanced neuroimaging, and immunological biomarkers improves diagnostic accuracy, while individualized disease-modifying treatment helps reduce inflammatory disease activity and delay disability progression. Comprehensive rehabilitation and regular neurological monitoring remain important components of long-term patient management.

References

[1] C. Walton et al., “Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition,” Multiple Sclerosis Journal, vol. 26, no. 14, pp. 1816–1821, 2020, doi: 10.1177/1352458520970841.

[2] A. J. Thompson et al., “Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria,” The Lancet Neurology, vol. 17, no. 2, pp. 162–173, 2018, doi: 10.1016/S1474-4422(17)30470-2.

[3] X. Montalban et al., “Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria,” The Lancet Neurology, vol. 24, no. 10, pp. 850–865, 2025, doi: 10.1016/S1474-4422(25)00270-4.

[4] X. Montalban et al., “ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis,” Multiple Sclerosis Journal, vol. 24, no. 2, pp. 96–120, 2018, doi: 10.1177/1352458517751049.

[5] S. L. Hauser et al., “Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis,” The New England Journal of Medicine, vol. 376, no. 3, pp. 221–234, 2017, doi: 10.1056/NEJMoa1601277.

[6] C. H. Polman et al., “Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria,” Annals of Neurology, vol. 69, no. 2, pp. 292–302, 2011, doi: 10.1002/ana.22366.

[7] M. P. McGinley, C. H. Goldschmidt, and A. D. Rae-Grant, “Diagnosis and treatment of multiple sclerosis: A review,” JAMA, vol. 325, no. 8, pp. 765–779, 2021, doi: 10.1001/jama.2020.26858.

[8] D. S. Reich, C. F. Lucchinetti, and P. A. Calabresi, “Multiple sclerosis,” The Lancet, vol. 391, no. 10130, pp. 1622–1636, 2018, doi: 10.1016/S0140-6736(18)30481-1.

[9] R. Dobson and G. Giovannoni, “Multiple sclerosis—A review,” European Journal of Neurology, vol. 26, no. 1, pp. 27–40, 2019, doi: 10.1111/ene.13819.

[10] F. D. Lublin et al., “Defining the clinical course of multiple sclerosis: The 2013 revisions,” Neurology, vol. 83, no. 3, pp. 278–286, 2014, doi: 10.1212/WNL.0000000000000560.

[11] X. Montalban et al., “Ocrelizumab versus placebo in primary progressive multiple sclerosis,” The New England Journal of Medicine, vol. 376, no. 3, pp. 209–220, 2017, doi: 10.1056/NEJMoa1606468.

[12] L. Kappos et al., “Siponimod versus placebo in secondary progressive multiple sclerosis,” The New England Journal of Medicine, vol. 378, no. 3, pp. 202–213, 2018, doi: 10.1056/NEJMoa1801931.

[13] National Institute for Health and Care Excellence, Multiple Sclerosis in Adults: Management, NICE Guideline NG220. London, U.K.: NICE, 2022. [Online]. Available: https://www.nice.org.uk/guidance/ng220.

[14] A. Bar-Or et al., “Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study,” Neurology, vol. 90, no. 20, pp. e1805–e1814, 2018.

[15] A. J. Solomon et al., “Application of the 2024 McDonald criteria: Earlier diagnosis and avoiding misdiagnosis of multiple sclerosis in a global setting,” Neurology, 2026.